A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

KRAScendo

Comprehensive Cancer Center Mainfranken

Lungentumoren

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

ras-Gen

KRAS

KRAS-G12C

Phase III

Herr Dr. Jens Kern

Frau Christiane Köhler

Frau Dr. med Barbara Schröder

Innere Medizin

Klinikum Würzburg Mitte gGmbH (Standort Missioklinik)

Zweitlinie

Advanced

Metastatic

Therapeutisch